Cover Image

Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial

Antiretroviral therapy (ART) suppresses HIV viral load in all body compartments and so limits the risk of HIV transmission. It has been suggested that ART not only contributes to preventing transmission at individual but potentially also at population level. This trial aims to evaluate the effect of...

Full description

Saved in:
Bibliographic Details
Main Authors: Iwuji, Collins C. (Author) , Tanser, Frank (Author) , Bärnighausen, Till (Author) , Newell, Marie-Louise (Author)
Format: Article (Journal)
Language:English
Published: 23 July 2013
In: Trials
Year: 2013, Volume: 14
ISSN:1468-6694
DOI:10.1186/1745-6215-14-230
Online Access:Volltext
Volltext
Get full text
Author Notes:Collins C. Iwuji, Joanna Orne-Gliemann, Frank Tanser, Sylvie Boyer, Richard J. Lessells, France Lert, John Imrie, Till Bärnighausen, Claire Rekacewicz, Brigitte Bazin, Marie-Louise Newell, François Dabis
Description
Summary:Antiretroviral therapy (ART) suppresses HIV viral load in all body compartments and so limits the risk of HIV transmission. It has been suggested that ART not only contributes to preventing transmission at individual but potentially also at population level. This trial aims to evaluate the effect of ART initiated immediately after identification/diagnosis of HIV-infected individuals, regardless of CD4 count, on HIV incidence in the surrounding population. The primary outcome of the overall trial will be HIV incidence over two years. Secondary outcomes will include i) socio-behavioural outcomes (acceptability of repeat HIV counselling and testing, treatment acceptance and linkage to care, sexual partnerships and quality of life); ii) clinical outcomes (mortality and morbidity, retention into care, adherence to ART, virologic failure and acquired HIV drug resistance), iii) cost-effectiveness of the intervention. The first phase will specifically focus on the trial’s secondary outcomes.
Item Description:Gesehen am 18.01.2018
Physical Description:Online Resource
ISSN:1468-6694
DOI:10.1186/1745-6215-14-230

Similar Items